Skip to main content
Premium Trial:

Request an Annual Quote

Protea, Gelcompany to Collaborate on Protein Analysis Products

NEW YORK (GenomeWeb News) – Protea Biosciences and Gelcompany, a wholly owned subsidiary of Australian firm Fluorotechnics, today said that they will collaborate on developing new technology for improved protein analysis.

Under the agreement, Protea has the right to distribute certain Gelcompany products in the North American life sciences market. The companies also said that they intend to collaborate on the co-development of new protein separation products for the global life sciences market.

"The addition of these products gives Protea a full line of superior gel-based protein separation products," Reid Asbury, director of sales and marketing for Morgantown, WV-based Protea Biosciences said in a statement. "We will be capable of addressing the entire market from sample preparation to mass spectrometry."

Terms of the agreement were not disclosed.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.